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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYGlioblastoma is a highly lethal cancer for which novel therapeutics are urgently needed. Two distinct subtypes of glioblastoma stem-like
cells (GSCs) were recently identified: mesenchymal (MES) and proneural (PN). To identifymechanisms to target themore aggressiveMES
GSCs, we combined transcriptomic expression analysis and kinome-wide short hairpin RNA screening of MES and PN GSCs. In compar-
ison to PN GSCs, we found significant upregulation and phosphorylation of the receptor tyrosine kinase AXL inMES GSCs. Knockdown
of AXL significantly decreased MES GSC self-renewal capacity in vitro and inhibited the growth of glioblastoma patient-derived xeno-
grafts. Moreover, inhibition of AXL with shRNA or pharmacologic inhibitors also increased cell death significantly more in MES
GSCs. Clinically, AXL expression was elevated in theMES GBM subtype and significantly correlatedwith poor prognosis inmultiple can-
cers. In conclusion, we identified AXL as a potential molecular target for novel approaches to treat glioblastoma and other solid cancers.INTRODUCTION
Glioblastoma (GBM) is the most common primary malig-
nant brain tumor in adults. Despite multimodal aggressive
therapies, survival of a vast majority of the patients is less
than 2 years with the 5-year survival rate as low as 5%
(Stupp et al., 2009). Previous efforts in the development
of therapeutics for GBM have largely depended on studies
with conventional GBM cell lines. While providing some
benefits, genetic and phenotypic drift is inevitable in these
long-term in vitro cell cultures. Importantly, the standard
GBM cell lines cannot recapitulate the heterogeneous
cellular populations of GBM (Ernst et al., 2009; Lee et al.,
2006). These limitations may partially explain the large
gap between promising in vitro data and disappointing
GBM clinical trial outcomes. The identification of effective
therapeutics has been hindered, in part, by the lack ofmore
clinically relevant GBM models. Tumor-initiating GBM
stem-like cells (GSCs) isolated from patients propagate
the heterogeneity of the original GBMs in immunocom-
promised mice and preserve specific genetic alterations
found in the original tumor (Hemmati et al., 2003; Singh
et al., 2004).
In the past decade, transcriptomic and methylation ana-
lyses have classified GBM tumors into several subtypes
(Phillips et al., 2006; Sturm et al., 2012; Verhaak et al.,
2010), including proneural (PN), classical, and mesen-
chymal (MES) GBMs. While these signatures are based onStemthe predominant gene expression patterns in the tumor
and correlate with mutation and epigenetic status, GBMs
are very heterogeneous, and data demonstrate the presence
of cells ofmultiple subtypes within a single tumor as well as
transitions between subtypes (Bhat et al., 2013; Patel et al.,
2014; Piao et al., 2013). Our work has classified themajority
of GSCs as MES or PN based on transcriptomic signatures.
In comparison to PN GSCs, MES GSCs display highly
aggressive and radioresistant phenotypes (Mao et al.,
2013). The core MES GSC gene signature also correlates
with poor GBM patient prognosis, indicating the impor-
tance of understanding molecular mechanisms driving
MES-specific biology. These patient-derived and subtype-
specific GSCs provide a powerful model for the heteroge-
neous human disease and future therapy development.
Kinases are often activated in cancer, indicating the po-
tential of kinase inhibitors for cancer therapy. Kinases con-
trol a wide variety of cell functions related to tumorigen-
esis, including survival/apoptosis, cell-cycle progression/
proliferation, stem cell maintenance, DNA damage repair,
cell motility/invasion, and therapeutic resistance. Indeed,
the discovery of oncogenic kinases and development of
target-specific inhibitors have already revolutionized the
treatment of certain groups of cancers, exemplified by the
success of Gleevec for chronic myeloid leukemia (Druker
et al., 2001). Protein kinases are now firmly established as
a major class of anti-cancer therapeutic targets. There has
been an explosion in the number of kinase inhibitorsCell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The Authors 899
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Figure 1. Patient-Derived PN and MES GSCs Used for In Vitro
Screening
(A) MRI captions taken pre-operation and post-operation of GBM
patients (upper) and H&E staining of the xenotransplanted cells in
NOD/SCID mice (lower). Magnification is 203 (left) and 1003
(right).
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promising data in preclinical drug development pipelines
(Zhang et al., 2009). While such success has not yet been
achieved for GBM, identification of kinases whose inhibi-
tion attenuates GSC properties may pave the way toward
novel therapeutics (Mellinghoff et al., 2012).
Here, we sought to identify new druggable therapeutic
targets for GBM. We combined transcriptome expression
profiling and loss-of-function approaches to identify hu-
man kinases that play differential roles in PN and/or MES
GSCs. Using a human kinome-wide lentiviral shRNA li-
brary, we identified 82 candidates that are essential for
the proliferation and viability of MES and/or PN GSC-con-
taining neurosphere cultures in vitro. Among them, 54 spe-
cifically regulated MES GSCs, underlining the dependence
of these GSC subtypes on differential oncogenic signals.
Subsequently, the receptor tyrosine kinases (RTKs) MET
and AXL were the only two genes that were significantly
differentially expressed in PN and MES GSCs and the
silencing of which caused a significantly different pheno-
type between PN andMES GSCs. Since an inhibitor against
AXL has recently entered phase I clinical trials for hemato-
poietic malignancy (Holland et al., 2010; Janning et al.,
2015), in this study, we decided to characterize AXL in
GSCs derived from GBM tumors.RESULTS
Patient-Derived GSCs Display MES or PN
Characteristics
The new ‘‘omics’’ data available for GBM suggesting the ex-
istence of several subtypes of GBM calls for detailed charac-
terization of the tumor models used in vitro. As previously
described (Mao et al., 2013), we successfully isolated GSCs
from GBM patients that can readily recapitulate the orig-
inal tumor’s phenotype in vivo (Figure 1A), express GSC
cell surfacemarkers (Figure 1B), and aremore self-renewing
than cells that are CD133 derived from the same tumor
(Figure 1C). Supervised clustering using The Cancer
Genome Atlas (TCGA) classification of the genome-wide
expression profiles obtained from the isolated GSCs(B) Representative FACS plots demonstrating expression of CD133
and CD44 PN GSCs (PN_528) and in MES GSCs (MES_83).
(C) Neurosphere formation assay of CD133+ versus CD133- PN_528
GBM cells. CD133 mRNA expression level in sorted cells was verified
by qRT-PCR (RT-PCR). Error bars represent the SD from three
technical replicates. Stem cell frequency was calculated by ELDA
analysis.
(D) Flowchart depicting the experimental procedure used to
investigate kinases whose silencing induces cell death or impairs
proliferation.
See also Figure S1.
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allowed us to classify them asMES or PN. Despite the abun-
dance of data provided, these profiling methods do not
yield information on genes that are directly involved in
cell fate decisions. To fill this gap, we combined data from
the genome-wide transcriptome profiles (Mao et al.,
2013) with a loss-of-function screen. Based on the highly
aggressive nature of MES GSCs, we specifically sought to
identify kinases that (1) impair the viability of MES GSCs
upon knockdown and (2) are differentially expressed in
MES GSCs in comparison to PN GSCs and neural progeni-
tor cells (NPs) derived from human fetal brains (Miyazaki
et al., 2012; Nakano et al., 2011) (Figure 1D).
Identification of Kinases that Impair BothMES and PN
GSC Viability and Alter Cell Cycle
In order to identify kinases that induce cell death and/or
cell-cycle arrest upon knockdown in GSCs of the PN and/
or MES subtype, we performed a lentiviral-based silencing
screen in vitro. We transduced the MES GSC line 83 and
the PNGSC line 528 with a subset of the TRC library specif-
ically targeting the human kinome. Using fluorescence-
activated cell sorting (FACS) analysis with propidium
iodide staining, we simultaneously detected cell death
and characterized the different phases of the cell cycle.
The significance of cell percentage in the G1, S, and G2
phases of the cell cycle was assessed after subtraction of
the SubG1 phase.
Kinases that were equally relevant in both MES and PN
GSCs were defined for each cycle phase separately. Analysis
was based on normalized data averaged from shRNAs from
both cell lines using one-sided adjusted p values (p < 0.05)
and a threshold of the median fold change (FC) plus two
median absolute deviations (MADs). Among the 668
kinases represented in the tested panel, knockdown of 7
kinases significantly increased the percentage of cells in
the SubG1 phase in MES and PN GSCs in comparison to
non-targeting controls (shNT), including FYN, RIPK3, and
the RET kinases (Figure S1A). Another 13 kinases signifi-
cantly altered the cell cycle by increasing the number
of cells entering the S (such as CARKL, EPHA5, and
MAP4K2) or the G2 phases (EGFR and DAPK2) in both
MES and PN GSCs (Figure S1B).
Identification of Kinases Specifically Regulating MES
or PN GSC Viability
In order to identify kinases that specifically regulate the
viability of MES or PN GSCs, ratios of SubG1 cell number
for each targeting shRNA to the shNT were calculated.
This analysis was based on one-sided adjusted p values
(p < 0.05) and a threshold of the median FC between PN
and MES +2 times the MAD. Several of the identified ki-
nases impaired viability of theMES GSCs only, as indicated
by increased percentages of cells in the SubG1 phase of theStemcell cycle (Figure 2A). For example, knockdown of genes
such as PKN3, PDPK1, and AXL significantly increased
the percentage of SubG1 cells in MES GSCs in comparison
to PN GSCs (Figures 2A and 2B). In contrast, targeting
CDC2L5 andDYRK2more strongly affected the percentage
of SubG1 cells in PN GSCs (Figures 2A and 2B). Of the top
three kinase hits in MES GSCs, AXLwas the only one high-
ly overexpressed inMESGSCs in comparison to PNGSCs at
the mRNA level in our microarray analysis (Figure 2A).
Therefore, our functional shRNA screen identified targets
whose importance would not have been recognized in
analysis of gene expression changes alone.
Identification of Kinases Specifically Altering MES or
PN GSC Cell Cycle Phase
After assessing the impact of the kinase directed shRNAs on
the SubG1 phase, we further analyzed the cell-cycle data to
identify kinases that differentially altered the G1, S, or G2
phases in MES or PN GSCs. We identified 70 kinases with
specific activity in at least one of these three cell-cycle
phases (Figure 2C). Differential cell-cycle effects of kinase
directed shRNAs were most prominent in the S phase for
MES GSCs, where GSK3A and AKT2 were found to signifi-
cantly reduce the percentage of dividing cells (Figure S2).
In PN GSCs, ROCK1, ALPK2, and MAP3K1 had differential
S-phase effects. Moreover, the knockdown of certain
kinases, such as IKBKE, PAK7, or FUK, resulted in effects
onmultiple cell-cycle phases, emphasizing the importance
of those genes for the proliferation of the targeted GSCs
(Figures 2C and S2). To assess the relevance of the identified
kinases, we performed a gene ontology analysis using the
DAVID bioinformatics resource. As depicted in Figure S3,
shRNAs that specifically impaired the MES GSC cell cycle
were directed against kinases enriched for known biolog-
ical processes regulating cell cycle. In contrast, shRNAs spe-
cifically altering the PNGSC cell cycle were directed against
kinases associated with neurological processes.
A Combination of Transcriptomics and Functional
Genomics Identifies AXL
Genome-wide mRNA expression profiling was performed
on GBM neurosphere lines each cultivated from six PN
and four MES high-grade glioma patients in triplicate
(Mao et al., 2013). Genes that showed an increase of
mRNA expression in MES GSCs of >15-fold as compared
with PN GSCs were designated as MES specific. To assess
the specificity of the gene expression for GSCs in compari-
son to non-neoplastic NPs, three independent cultures
from a normal NP line were included in the analysis. We
selected candidate genes with mRNA expression >7-fold
higher in MES GSCs compared with the NPs. In order to
identify genes that selectively impair the viability of MES
GSCs, we compared the list of identified genes based onCell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The Authors 901
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Figure 2. Knockdown of a Subset of Kinases Differentially
Induces Cell Death in MES or PN GSCs
(A) List of kinases that induce cell death significantly (*, adjusted
p < 0.05) in MES GSCs (red) or in PN GSCs (blue). mRNA expression
FC between PN and MES GSCs is indicated on the right side of the
heatmap.
(B) Stacked bar charts of the top two genes inducing cell death in
MES (above) or in PN (below) GSCs. Average of the shNT used for
normalization and the shRNAs targeting the indicated gene is
shown. Error bars represent the SD.
902 Stem Cell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The Authothese transcriptomics data with the ones from the func-
tional genomics screen. The genes encoding the AXL RTK
(AXL) and the MET Proto-Oncogene (MET) proteins were
the only two genes that appeared in both datasets (Figures
1C, 2A, 2C, and 2D). As recent studies indicate that AXL is a
potentially attractive therapeutic target and one of its
kinase inhibitors has entered the phase I clinical trial for
hematologic malignancy, we focused on AXL for further
characterization in GSCs in this study.
AXL Is Highly Expressed in MES but Not PN GSCs
To characterize the pathophysiological role of AXL in MES
and PN GSCs, we further analyzed the data from the tran-
scriptome microarray (Mao et al., 2013). In these data,
including 18 patient-derived PN GSC samples, 12 patient-
derived MES GSC samples, 5 astrocyte samples, and 3
normal NPs, all 12 MES GSC samples revealed high expres-
sion of AXL. In contrast, 18 PN samples showed either
undetectable AXL expression by microarray analysis or
substantially lower expression (Figure 3A). These results
were confirmed by qRT-PCR using three PN and three
MES GSC samples (Figure 3B). AXL expression in MES
GSCs was also elevated in comparison to NPs (Figure 3A).
Concordant with the mRNA expression, AXL protein
expression was increased in MES compared with PN
GSCs, as determined via immunoblotting (Figure 3C) and
immunofluorescence (Figure 3D). In addition, the phos-
phorylated form of AXL (pY779) was only detected in
MES GSCs (Figures 3C and 3D), suggesting that the AXL
pathway is specifically activated in MES but not PN GSCs.
Our data are in accordance with other datasets of patient-
derived GBM spheres (Figures 3E and 3F; Bhat et al.,
2013; De Bacco et al., 2012) and GBM patient specimens
(Figures 3G and 3H; Brennan et al., 2013; Sturm et al.,
2012). Together, these data demonstrate that AXL is prefer-
entially expressed and activated in MES GBM.
Knockdown of AXL Decreased Clonogenicity of MES
GSCs In Vitro
To further confirm the high-throughput screening results
indicating that AXL shRNA increased the number of
SubG1 cells (Figure 4A) and to investigate the function of
AXL in MES GSCs, we transduced two MES GBM sphere
samples (83 and 1123) with two gene-specific shRNAs for
AXL (shAXL#1 and shAXL#2) and shNT as a control. The(C) Venn diagram grouping kinases whose silencing induces a
significant change of the cell-cycle phases specific to MES or to PN
GSCs (see also Figures S2 and S3). Asterisks highlight 54 kinases
whose silencing altered the cell cycle specifically in MES GSCs.
(D) Ranking of AXL according to the cell number FC in SubG1 in MES
and PN GSCs. Data are all initially normalized to the non-targeting
shRNA.
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knockdown of AXL protein by the directed shRNAs after
transduction was confirmed using immunoblotting (Fig-
ure 4B). In vitro growth assays demonstrated that knock-
down of AXL decreased the growth of 83 and 1123 MES
GSCs (Figure 4C) in comparison to the shNT. In vitro
limiting dilution assays showed a decreased capacity to
form neurospheres in 83 and 1123 GBM upon AXL knock-
down, indicating a reduced clonogenicity of the GSCs (Fig-
ures 4D and 4E). These observations were concordant with
an increase in apoptosis, as demonstrated by significantly
higher Caspase 3/7 activity with AXL targeting (Figure 4F).
As suggested by its expression level, the knockdown of AXL
in the PNGSC line did not impair clonogenicity (Figure 4E)
nor increase apoptosis (Figure 4F). Interestingly, MES GSCs
also showed higher sensitivity than the PN_528GSC line to
BGB324, an AXL inhibitor (Figure 4G). Sigmoidal dose-
response analysis indicated a lower IC50 in the MES versus
the PN GSCs tested (IC50 of 1.027 and 2.035 mM, respec-
tively). The specificity of BGB324 for AXL was assessed by
the level of AXL phosphorylation with and without inhib-
itor treatment (Figure 4G).
AXL Regulates In Vivo Tumorigenicity of MES GSCs
We next assessed the role of AXL in MES GSC tumorigenic
potential. To this end, we knocked down AXL in 83 and
1123 GSCs using shALX#2 and used shNT as a control.
Transduced cells were orthotopically injected into the stria-
tum of immunocompromised mice. Mice receiving
shAXL#2 transduced 83 or 1123 GSCs did not show any
signs of tumors 2 weeks after transplantation, whereas
mice injected with shNT transduced cells had large GBMs
(Figure 5A). Knockdown ofAXL also significantly increased
the survival of mice until the development of neurological
signs in comparison to shNTcontrols (n = 12 with 83 GBM,
p = 0.0005, with log-rank test, and n = 10 with 1123 GBM,
p = 0.0018, with log-rank test). However, animals that
received shAXL-infected 83 or 1123 GSCs developed
tumors about a month after transplantation (Figure S4).
These results suggest that AXL is an important regulator
of MES GBM growth, but not absolutely required for tumor
initiation.
AXL Expression Correlates with CD44 Expression and
Is Highly Expressed in Glioma Samples
In view of the importance of AXL for the viability of GSCs
from the MES subtype, we investigated whether AXL
mRNA expression correlated with the mRNA expression
of the MES marker CD44. The RNaseq data generated by
the TCGA Research Network (http://cancergenome.nih.
gov/) showed a significant correlation between the expres-
sion of both genes (Figure 6A). Interestingly, the silencing
of AXL in two MES GSC lines (83 and 1123) decreased
the mRNA expression of CD44 (Figure 6B), suggesting aStemco-regulation of both genes. These data were confirmed at
the protein level by immunofluorescent staining of ortho-
topically injected 83 GSCs transduced with shNTor shRNA
targeting AXL (shAXL#2) (Figure 6C). Supporting this
finding, in orthotopically xenografted tumors derived
from patient GSCs, AXL co-expressed with CD44 preferen-
tially in perinecrotic pseudopallisading areas (Figure S5).
Moreover, AXL and CD44 co-expression correlated with
the clinical survival time of glioma patients. The data
generated by TCGA Research Network, visualized using
the GBM-Bio Discovery Portal, shows that the co-upregula-
tion of AXL and CD44 is a predictor of poor survival in
GBM patients (Figure 7A).
Finally, we assessed the relevance of AXL as a potential
therapeutic target for GBM and other tumor entities. Eval-
uating the Sun et al. (2006) dataset, elevated AXL expres-
sion was observed in glioma compared with non-tumor
(n = 23 non-tumor group; n = 7 grade II astrocytoma; n =
19 grade III astrocytoma; n = 81 GBM group; p < 0.01, p <
0.05, and p < 0.0001, respectively, probeset: 202686_s_at)
(Figure 7B). Supporting this expression pattern, we found
that AXL was highly expressed in high-grade gliomas,
including GBM, but not in normal brain tissues or lower
grade gliomas (Figure 7C), as determined by evaluating
phospho-AXL immunoreactivities in glioma patient sec-
tions. In the GBM samples from the Gravendeel et al.
(2009) dataset through the R2 microarray analysis and
visualization platform (http://r2.amc.nl), AXL expression
trended toward poor survival of GBM patients, although
the data did not meet statistical significance (Figure 7D;
p = 0.060 with log-rank test). In silico analysis of existing
datasets for other cancer types, including ovarian, colon,
pancreatic, and Burkitt’s lymphoma cancer, also linked
AXL to poor prognosis, although this was not true for every
tumor type or dataset (Figures 7E–7H) (Collisson et al.,
2011; Hummel et al., 2006; Smith et al., 2010; Tothill
et al., 2008). Collectively, these results indicate that AXL
is a potential molecular target for anti-cancer therapy.DISCUSSION
In this study, we took a stepwise approach with transcrip-
tome expression analysis and a functional shRNA screen
in order to identify common and differential regulators of
PN and MES GSC growth.
AXL is a member of the TAM (TYRO3-, AXL-, MER-TK)
subfamily of RTKs (O’Bryan et al., 1991). This family shares
structural homology, including a conserved sequence
within the kinase domain (Linger et al., 2008). In contrast
to little or no expression in normal brain tissue, aberrant
AXL expression in GBM has been described, raising the
possibility that AXL could be an attractive therapeuticCell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The Authors 903
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Figure 3. AXL Is More Highly Expressed in MES Than PN GSCs
(A) Microarray analysis of AXL mRNA expression in PN GSCs from individual patients (n = 18), MES GSCs (n = 12), astrocytes (n = 5), and
neural progenitors (n = 3) (Mao et al., 2013) (*p < 0.05; **p < 0.01; ****p < 0.0001; Mann Whitney t test in comparison to MES GSCs).
(B) AXL mRNA expression as determined by qRT-PCR in PN (n = 3) and MES (n = 3) (***p < 0.0001; t test). Error bars represent the SD from
three technical replicates.
(legend continued on next page)
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target for GBM. Earlier work has established the physiolog-
ical roles of AXL in glioma cell lines using both in vitro cell
culture systems and in vivo xenografted tumor models
(Keating et al., 2010; Vajkoczy et al., 2006). Gene-specific
knockdown of AXL has been shown to induce cell
apoptosis, decrease cell proliferation and migration, and
improve sensitivity to temozolomide—the current first-
line chemotherapy for GBM (Keating et al., 2010; Vajkoczy
et al., 2006). Our data demonstrate that a subset of GSCs in
GBM tumors—MES but not PN GSCs—is sensitive to AXL
knockdown both in vitro and in vivo. Supporting these dif-
ferential sensitivities, a phosphorylated form of AXL is de-
tected only in the MES GSCs. Knubel et al. (2014) recently
reported that foretinib treatment hindered tumor growth
in a mouse model of GBM using the glioma cell line
U251 in vivo. Notably, foretinib is a multikinase inhibitor
with the most potent effect on another TAM RTK, MER-
TK, with comparable inhibitory effects on AXL, c-Met,
and VEFRR2/KDR (Liu et al., 2009; Qian et al., 2009).
Several phase II clinical trials with foretinib are in progress,
addressing breast, liver, renal, gastric, and other cancers
(Choueiri et al., 2013; Liu et al., 2009; Shah et al., 2013).
Zhang et al. (2012) recently identified that activation of
the AXL kinase is a mechanism by which resistance is ac-
quired to EGFR-targeted tyrosine kinase inhibitors (TKIs)
in EGFRmutant non-small-cell lung cancers. In some cases,
they found that AXL upregulation occurs in the context of
what appeared to be epithelial toMES transition (EMT) and
EMT-associated transcriptional reprogramming, leading to
acquired resistance. Vuoriluoto et al. (2011) also reported
similar data for AXL-mediated EMT-like changes in breast
cancer cells. These studies raise the possibility that second-
ary molecular events may occur in GBM cells or GSCs that
facilitate escape fromAXL targeting therapies. For example,
AXL inhibition may lead to the activation of other TAM
family members such as MerTK and Tyro3. Indeed, TAM
family members form heterodimers and cross-talk with
each other (Linger et al., 2008). Since they share the com-
mon ligand Gas6 and the common downstream signaling
pathways PI3K and MAPK, targeting AXL alone may lead
to a switch to other TAM familymembers to persist the acti-(C) Representative western blot of total AXL and phospho-AXL (pY77
1123).
(D) Representative immunofluorescent images of total AXL and phosp
(E and F) mRNA expression of AXL as determined by gene expression pro
(**p < 0.01, unpaired t test) and (F) Bhat et al. (2013) (*p = 0.0124
(G) AXL expression is higher in the MES subtype (n = 18) compared w
determined by RNaseq data from individual patients (TCGA dataset, cla
and maximum data points (*p < 0.05; unpaired t test).
(H) AXL is higher in the MES subtype (n = 55) compared with the classi
neural (n = 28) subtype, as determined by RNaseq data from individu
unpaired t test). Error bars represent the minimum and maximum dat
Stemvation of the same ligand-driven oncogenic pathways. Our
data illustrate thatAXL silencing significantly prolongs sur-
vival of mice bearing GSC-derived brain tumors, yet even-
tually these mice die due to tumor burden. As tumors can
arise from AXL-shRNA-transduced MES GSCs, it will be
important to investigate how these tumors escape from
AXL inhibition in additional studies. Of note, foretinib
treatment reduces growth of U251-derived mouse subcu-
taneous tumors, whereas when this treatment is discontin-
ued, tumors showed a quick upturn reaching growth rates
even more aggressive than naive tumors (Knubel et al.,
2014). These studies indicate a risk for advancing malig-
nancy if tumors are treated with AXL inhibition solely.
Future studies will need to explore downstream molecular
changes after AXL inhibition in GSCs and GSC-derived
tumors in order to avoid establishing acquired resistance
in GBM patients after AXL-targeted therapies.
In conclusion, our experimental setting allowed the
identification of differences in survival and proliferation
pathways between PN and MES GSCs. The sensitivity of
MESGSCs to the silencing ofAXLhighlights its importance
in this subgroup of GSCs and suggests its potential for use
as a therapeutic target.EXPERIMENTAL PROCEDURES
GSC Isolation and Cell Culture
GSC samples were collected at The Ohio State University in accor-
dance with an institutional review board-approved protocol.
GSCs were isolated as previously described (Gu et al., 2013;
Mao et al., 2013). Neurospheres were cultured in DMEM/F12
(Invitrogen) containing 2% B27 supplement (Invitrogen) (vol/
vol), heparin (2.5 mg/ml), basic fibroblast growth factor (bFGF)
(Peprotech, 20 ng/ml), and epidermal growth factor (EGF) (Pepro-
tech, 20 ng/ml). bFGF and EGF were added twice a week. The
phenotypes of these neurospheres were characterized according
to the methods described previously (Guvenc et al., 2013; Jijiwa
et al., 2011). All of the neurospheres used in this study were
maintained <30 passages. The human fetal neural stem cell
sample (16wf) was established at the University of California at
Los Angeles as described previously (Miyazaki et al., 2012;
Nakano et al., 2011). Astrocytes were derived from fetal9) expression in PN (528, 19, and 84) and MES GSCs (83, 326, and
ho-AXL staining in MES and PN GSCs (scale bar represents 50 mm).
filing from previously published datasets: (E) De Bacco et al. (2012)
, unpaired t test).
ith the IDH (n = 5), RTKI (n = 5), and RTKII (n = 28) subtypes, as
ssification by Sturm et al., 2012). Error bars represent the minimum
cal (n = 42), PN (n = 31), and G-CIMP (n = 8) subtypes but not to the
al patients (TCGA dataset) (*p < 0.05, **p < 0.01, ****p < 0.0001;
a points.
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neurospheres (16wf) (Guvenc et al., 2013; Miyazaki et al., 2012;
Nakano et al., 2011).
Lentivirus Production and Transduction
Screening of the kinase panel shRNA from The Mission RNAi
library (Sigma-Aldrich) was performed in 96-well plates as previ-
ously described (Goidts et al., 2012). Briefly, DNA preparations
were obtained using a large-scale plasmid purification kit (QIAGEN
and Roche). HEK293T packaging cells were co-transfected with the
pLKO.1 vector encoding the shRNA and the helper plasmids for
virus production (psPAX2 and pMGD2), using Trans-IT (Mirus).
Before transduction, spheres were dissociated mechanically (83
MES GSC) or with trypsin (528 PN GSC). Cells were seeded in
96-well plates at 10,000 cells per well in a final volume of 100 ml
and transduced at a multiplicity of infection of 10. At 24 hr after
transduction, medium was renewed upon plate centrifugation
for 2 min at 800 rpm. Further details about the controls are avail-
able in the Supplemental Information.
The production of single shRNAs targeting AXL (shAXL#1:
GCGGTCTGCATGAAGGAATTT, shAXL#2: GCTGTGAAGACGAT
GAAGATT) was performed in 6-cm petri dishes. After 72 hr,
produced lentiviruses were concentrated by ultracentrifugation
of the HEK293T supernatant at 25,000 rpm.
High-Throughput FACS Analysis
Cell-cycle analysis was performed using a propidium iodide (PI)
staining assay. Briefly, cells were fixed using 70% ethanol 5 days
after viral transduction. After incubation at 4C overnight, plates
were centrifuged at 1,000 rpm for 5 min. Ethanol was removed,
and 200-ml room temperature cell-cycle staining reagent (0.1%
Triton X-100,PBS, 200-mg/ml DNase-free RNase, 250-mg/ml PI)
was added. Cells were resuspended, and the plates were incubated
at room temperature for 30 min, followed by cell-cycle analysis
using a flow cytometer equipped with a high-throughput sampler.
To minimize potential artifacts caused by edge effects, the outer-
most wells were not used.Figure 4. AXL Is Required for the Growth and Clonogenicity of M
(A) Average FC of cell number in different phases of the cell cycle upon
5 independent shRNAs targeting AXL.
(B) Representative western blot results of shNT and shAXL samples fro
expression was quantified and normalized to GAPDH (lower).
(C) In vitro growth assay in 83 and 1123 MES GSCs transduced with shN
at days 2, 4, and 6. Error bars represent the SD of three technical rep
(D) Representative pictures of GSCs cultivated as neurospheres transd
taken 5 days after transduction. Scale bar represents 60 mm.
(E) Limiting dilution neurosphere formation assay in MES (83 and 1123
shAXL#2 in ten technical replicates. Readout was performed 12 day
regression analysis). Stem cell frequency was calculated by ELDA ana
(F) Caspase activity assay of PN 528 GSCs and MES GSCs (83 and 112
Results are normalized to shNT. Error bars represent the SD of three bio
of caspase activity for each shRNA in the PN GSC line with the MES GS
t test).
(G) AXL inhibitor treatment effects on MES_83 and PN_528 GSC gro
indicated concentrations (IC50 of 1.027 mM [MES_83] and 2.035 mM [
Western blot phospho-AXL expression in MES 83 GSCs with or withou
StemGene Expression Analysis
Gene expression data were downloaded from GEO datasets:
Mao et al. (2013) (GSE 67089), Bhat et al. (2013) (GSE49009), De
Bacco et al. (2012) (GSE36426), Sun et al. (2006) (GSE4290).
R Bioconductor was used for the analysis of raw .cel files. The
heatmap of transcriptomics analysis was made by Cluster and
Treeview.
In Vitro Proliferation and Apoptosis Assay
After 83 and 1123 MES GSCs had been infected with AXL shRNA
lentivirus for 5 days, 1,000 cells were seeded into wells of 96-well
plates. AlamarBlue (Life Technologies) was used for the evaluation
of cell number following the protocol provided bymanufacturer at
different time points (days 0, 2, 4, and 6). In order to measure
apoptosis upon AXL silencing, 5,000 cells were seeded per well
in a 96-well plate and transduced with shNT or shAXL. After
4 days, caspase 3 and 7 activities were measured using a Caspase-
Glo 3/7 Assay (Promega), according to the manufacturer’s instruc-
tions. BGB324 was used to treat cells at final concentrations of
0.01, 0.1, 0.5, 1, 2, 5, 10, and 20 mM. After dissociation into
single-cell suspensions, 1,000 cells per well were seeded into 96-
well plates. At 72 hr after treatment, cell viability was measured
using AlamarBlue.
Limiting Dilution Neurosphere Formation Assay
After infectionwith shNTand shAXL lentivirus as described above,
83 and 1123MES GSCs were seeded into 96-well plates at densities
of 1, 10, 20, 30, 40, and 50 cells per well. Spheres with diameters
>60 mm were counted at day 7 under an inverted microscope
with a digital camera (Olympus). Extreme limiting dilution assay
(ELDA) analysis were performed using the software available at
http://bioinf.wehi.edu.au/software/elda/.
Western Blot Analysis
A detailed protocol can be found in the supplemental information.
The membranes were treated with anti-AXL (Cell SignalingES GSCs
AXL knockdown normalized to shNT. Error bars represent the SD from
m 83 and 1123 GSCs with GAPDH as a loading control (upper). AXL
T or two different shRNA targeting AXL (shAXL#1 and #2) measured
licates.
uced with shNT or AXL directed shAXL#1 or shAXL#2. Pictures were
) and PN (528) GSCs. Cells were transduced with shNT or shAXL#1 or
s after transduction (*p < 0.5; **p < 0.01; ***p < 0.001; linear
lysis.
3) 4 days after transduction with shNT and shAXL#1 and shAXL#2.
logical replicates. Significance was assessed by comparing the rate
C lines (N.S. = not significant; ***p < 0.005; ****p < 0.001; paired
wth. Results were obtained 72 hr after BGB324 treatment at the
PN_528]). Error bars represent the SD of three technical replicates.
t BGB324 treatment for 24 hr. b-Actin served as loading control.
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Figure 5. AXL Contributes to Tumor Prop-
agation of MES GSCs
(A) Representative photographs of mouse
brains injected with 83 and 1123 GSCs
transduced with shNT or shAXL#2 and
representative H&E staining of shNT and
shAXL mouse xenografts at the indicated
time points.
(B) Kaplan-Meier survival curves for mice
injected with 83 and 1123 GSCs transduced
with shNT (n = 6 and n = 5, respectively) and
shAXL#2 (n = 6 and n = 5, respectively) (see
also Figure S4).#8661), anti-phospho-AXL (R&D AF2228), and anti-GAPDH anti-
bodies (Abcam ab9482). Protein expression was visualized with
Amersham ECL western blot system (GE Healthcare Life Sciences).
GAPDH served as a loading control, and band intensity was quan-
tified using Image J software.
RNA Extraction and qRT-PCR
Total RNA was prepared using RNeasy mini kit (QIAGEN) accord-
ing to the manufacturer’s instructions. A detailed protocol and
primer sequences are listed in the Supplemental Information.
Immunohistochemistry
Immunohistochemistry (IHC) was carried out as previously
described (Jijiwa et al., 2011). After perfusion with ice-cold PBS
and 4% (wt/vol) paraformaldehyde (PFA), mice brains were fixed
in 4% PFA for 24 hr and then transferred into 10% formalin. Tissue
embedding and sectioning were performed at the Comparative908 Stem Cell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The AuthoPathology and Mouse Phenotyping Shared Resource of Ohio
State University. The slides were treated with primary antibody
overnight at 4C and incubated with a horseradish peroxidase
(HRP)-conjugated secondary antibody for 1 hr at room tem-
perature. Slides incubated without primary antibodies served
as negative controls. Chromogenic visualization followed using a
DAB substrate kit (Vector), and nuclei were counterstained with
hematoxylin.Immunocytochemistry and Immunofluorescence
For immunocytochemistry, neurospheres were dissociated into
single cells and seeded onto coverslips coated with 0.5% laminin
(23 104 per well). After 24 hr, the cells were fixed with 4% (wt/vol)
PFA, blocked with 1% BSA containing 0.3% Triton-X, and treated
with primary antibody at 4C overnight. The cells were then
incubated with Alexa Flour 555-conjugated secondary antibody
for 45 min at room temperature. Nuclei were counterstainedrs
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TCGA Glioblastoma Dataset Figure 6. AXL Expression Correlates with
CD44
(A) AXL mRNA expression significantly cor-
relates with CD44 mRNA expression. RNaseq
data from n = 169 GBM patients are repre-
sented.
(B) Relative mRNA expression of AXL and
CD44 upon AXL knockdown. Data are
normalized to shNT and are represented as
mean of technical replicates ± SD.
(C) Immunofluorescent staining of AXL and
CD44 on MES_83 GSCs in the mouse brain
with (shAXL#2) or without (shNT) knock-
down of AXL. Tumors were removed 24 days
after injection (see also Figure S5). Scale bar
represents 50 mm.with Hoechst 35228, and the coverslips were mounted with anti-
fade reagent (Life Technologies). Images were captured using a
fluorescence uprightmicroscope (Olympus DP71). Identical filters,
objectives, and acquisition parameters were used for each
experiment.StemFor immunofluorescence, mouse brains were fixed, embedded,
and sectioned as described above. After blocking for 1 hr with
10% normal goat serum, the slides were co-incubated with rabbit
anti-AXL (Cell Signaling, #8661) and mouse anti-CD44 antibody
(Cell Signaling, #3570) overnight at 4C and treated withCell Reports j Vol. 4 j 899–913 j May 12, 2015 j ª2015 The Authors 909
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Figure 7. AXL Is Highly Expressed in Clinical High-Grade Glioma Tumors
(A) Survival analysis based on the impact of the multi-gene prognostic index. Affymetrix data generated by TCGA Research Network that are
available at the TCGA data portal were used. Visualization of the data was performed using the GBM-BioDP (Celiku et al., 2014).
(B) AXL is more highly expressed in astrocytoma and GBM than in non-tumor tissue (Sun et al., 2006) (n = 23 non-tumor; n = 7 grade II;
n = 19 grade III; n = 81 GBM). *p < 0.05, **p < 0.01, ****p < 0.0001 (Mann-Whitney test).
(legend continued on next page)
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anti-mouse Alexa Fluor 488 (Cell Signaling) and anti-rabbit Alexa
Fluor 555 (Cell Signaling) conjugated secondary antibodies for
1 hr at room temperature. Counterstaining was performed with
Hoechst 35228 (Cell Signaling), and images were captured as
described above.In Vivo Tumor Propagation
Six-week-old nudemicewere obtained from the animal research fa-
cilities of The Ohio State University. All animal experiments were
carried out at The Ohio State University under an Institutional
Animal Care and Use Committee (IACUC)-approved protocol ac-
cording to NIH guidelines (IACUC Number: 2009A0241); 83 and
1123 MES GSC suspensions expressing shNT and shAXL#2 (1 3
104 cells in 2 ml of PBS) were injected into the brains of nude
mice as previously described (Guvenc et al., 2013; Miyazaki et al.,
2012; Nakano and Kornblum, 2009). Animals were monitored
until the development of neuropathological symptoms.Statistical Analysis
For analysis of FACS data, measurements with less than 2,000 cell
counts were excluded. Measurements were standardized by the
average of the non-target shRNA measurements separately for
each plate. Ratios were log2 transformed to more closely follow a
normal distribution. Relevant kinase directed shRNAs were identi-
fied using the empirical Bayes approach (Smyth, 2004) based on
moderated t statistics as implemented in the Bioconductor package
limma (Smyth, 2005). All p values were adjusted for multiple
testing using Benjamini-Hochberg correction in order to control
the false discovery rate. Adjusted p values below 0.05 were consid-
ered statistically significant. All analyses were carried out using
software R 3.0.1. (RDCTeam, 2011). A detailedmethod is described
in the Supplemental Information.
Functional data were analyzed using Graphpad prism 6 and pre-
sented as mean ± SD. Statistical significance of Kaplan-Meier sur-
vival plot was determined by log-rank test; p < 0.05 was considered
as statistically significant for all statistical methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and five figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2015.03.005.
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